loading
Schlusskurs vom Vortag:
$9.07
Offen:
$9.08
24-Stunden-Volumen:
1.23M
Relative Volume:
0.85
Marktkapitalisierung:
$1.21B
Einnahmen:
$175.51M
Nettoeinkommen (Verlust:
$-78.02M
KGV:
-16.85
EPS:
-0.53
Netto-Cashflow:
$-34.18M
1W Leistung:
+3.48%
1M Leistung:
+11.21%
6M Leistung:
+11.62%
1J Leistung:
+59.46%
1-Tages-Spanne:
Value
$8.91
$9.12
1-Wochen-Bereich:
Value
$8.55
$9.36
52-Wochen-Spanne:
Value
$5.195
$10.67

Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile

Name
Firmenname
Aurinia Pharmaceuticals Inc
Name
Telefon
250-744-2487
Name
Adresse
#140, 14315 - 118 AVENUE, EDMONTON, BC
Name
Mitarbeiter
300
Name
Twitter
@AuriniaPharma
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
AUPH's Discussions on Twitter

Vergleichen Sie AUPH mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
AUPH
Aurinia Pharmaceuticals Inc
8.93 1.23B 175.51M -78.02M -34.18M -0.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-11-04 Herabstufung Oppenheimer Outperform → Perform
2022-05-05 Fortgesetzt Cantor Fitzgerald Overweight
2021-12-10 Hochstufung Oppenheimer Perform → Outperform
2021-10-28 Herabstufung Oppenheimer Outperform → Perform
2021-01-25 Bestätigt H.C. Wainwright Buy
2020-11-03 Bestätigt H.C. Wainwright Buy
2020-06-17 Eingeleitet BTIG Research Buy
2020-05-05 Eingeleitet Cowen Outperform
2020-01-10 Eingeleitet Jefferies Buy
2019-12-16 Bestätigt H.C. Wainwright Buy
2018-03-16 Bestätigt Cantor Fitzgerald Overweight
2018-02-08 Eingeleitet RBC Capital Mkts Outperform
2017-10-30 Bestätigt H.C. Wainwright Buy
2017-05-18 Bestätigt H.C. Wainwright Buy
2017-04-11 Eingeleitet Cantor Fitzgerald Overweight
2017-03-22 Bestätigt FBR & Co. Outperform
2016-12-30 Bestätigt H.C. Wainwright Buy
2016-08-17 Bestätigt H.C. Wainwright Buy
2016-06-30 Eingeleitet H.C. Wainwright Buy
2015-05-08 Eingeleitet MLV & Co Buy
Alle ansehen

Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten

pulisher
05:39 AM

What is Aurinia Pharmaceuticals Inc. company’s growth strategyUnlock powerful portfolio optimization tools - jammulinksnews.com

05:39 AM
pulisher
04:48 AM

What makes Aurinia Pharmaceuticals Inc. stock price move sharplyAccelerated wealth expansion - jammulinksnews.com

04:48 AM
pulisher
Jul 26, 2025

Can Aurinia Pharmaceuticals Inc. stock recover from recent decline200 Percent Gain Alert - Metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

Aurinia Pharmaceuticals Inc. Stock Analysis and ForecastFastest-growing stock picks - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Will Aurinia Pharmaceuticals Inc. stock split in the near futureMarket-leading growth rates - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Aurinia Pharmaceuticals Inc. stockRapid growth opportunities - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

When is the best time to buy Aurinia Pharmaceuticals Inc. stockSuperior profit margins - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

Is Aurinia Pharmaceuticals Inc. a good long term investmentTremendous gains - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

What drives Aurinia Pharmaceuticals Inc. stock priceUnmatched profit growth - Autocar Professional

Jul 24, 2025
pulisher
Jul 22, 2025

Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025 - BioSpace

Jul 22, 2025
pulisher
Jul 22, 2025

Aurinia Pharmaceuticals to Announce Q2 2025 Financial Results - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

Aurinia Pharmaceuticals: LUPKYNIS Growth and AUR200 Pipeline Fuel Long-Term Value - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting - Yahoo.co

Jul 22, 2025
pulisher
Jul 20, 2025

(AUPH) Technical Data - news.stocktradersdaily.com

Jul 20, 2025
pulisher
Jul 18, 2025

Aurinia Pharmaceuticals (NASDAQ:AUPH) Delivers Shareholders Favorable 52% Return Over 1 Year, Surging 5.5% in the Last Week Alone - 富途牛牛

Jul 18, 2025
pulisher
Jul 17, 2025

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Yahoo

Jul 17, 2025
pulisher
Jul 15, 2025

How Aurinia Pharmaceuticals Inc. stock performs during market volatilityFree Stock Investment Discussion Area - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Aurinia Pharmaceuticals Inc. stock attracts strong analyst attentionReal Trader Insights - Newser

Jul 15, 2025
pulisher
Jul 10, 2025

How did AUPH's Q3 2024 earnings surprise impact short-term traders? - AInvest

Jul 10, 2025
pulisher
Jul 09, 2025

Trading (AUPH) With Integrated Risk Controls - news.stocktradersdaily.com

Jul 09, 2025
pulisher
Jul 08, 2025

Wheat from chaff in BAFF: APRIL’s advent for Aurinia? - BioWorld MedTech

Jul 08, 2025
pulisher
Jul 07, 2025

The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity (NASDAQ:AUPH) - Seeking Alpha

Jul 07, 2025

Finanzdaten der Aurinia Pharmaceuticals Inc-Aktie (AUPH)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Aurinia Pharmaceuticals Inc-Aktie (AUPH) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Greenleaf Peter
Chief Executive Officer
Mar 03 '25
Sale
8.00
195,593
1,564,744
1,953,892
Greenleaf Peter
Chief Executive Officer
Mar 04 '25
Sale
7.92
164,947
1,306,380
1,788,945
Keenan Greg
Chief Medical Officer
Mar 03 '25
Sale
8.00
12,239
97,912
161,789
Miller Joseph M
Chief Financial Officer
Mar 03 '25
Sale
8.00
61,859
494,872
633,515
Miller Joseph M
Chief Financial Officer
Mar 04 '25
Sale
7.92
56,154
444,740
577,361
Robertson Stephen P.
EVP, General Counsel
Mar 03 '25
Sale
8.00
64,872
518,976
566,883
Robertson Stephen P.
EVP, General Counsel
Mar 04 '25
Sale
7.92
57,607
456,247
509,276
Donley Matthew Maxwell
Chief Operating Officer
Mar 03 '25
Sale
8.00
65,902
527,216
739,456
Donley Matthew Maxwell
Chief Operating Officer
Mar 04 '25
Sale
7.92
58,991
467,209
680,465
TANG KEVIN
Director
Mar 04 '25
Buy
7.96
748,038
5,953,304
10,029,500
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Kapitalisierung:     |  Volumen (24h):